These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33058629)

  • 1. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
    Lupu J; Herrscher H; Robert C
    Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of melanoma with immune checkpoints inhibitors].
    Lupu J; Hamann P; Routier É; Robert C
    Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel adjuvant options for cutaneous melanoma.
    Dimitriou F; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
    Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
    Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
    Herrscher H; Robert C
    Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
    Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
    Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab use for the treatment of advanced melanoma.
    Specenier P
    Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials.
    Bersanelli M; Petrelli F; Buti S; Stanganelli I
    Hum Vaccin Immunother; 2022 May; 18(3):1902723. PubMed ID: 33881961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
    El Rassy E; Farhat F; Kattan J
    Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of pembrolizumab for resected stage III melanoma.
    Pham F; Dalle S
    Expert Opin Drug Saf; 2020 Oct; 19(10):1221-1227. PubMed ID: 32799585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
    Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.
    Krueger O; Eisenburger R; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Theurer S; Brodin B; Schadendorf D; Ugurel S
    Front Immunol; 2024; 15():1369190. PubMed ID: 38807589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
    Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
    Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.